SEC Form SC 13G/A filed by Viracta Therapeutics Inc. (Amendment)

$VIRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VIRX alert in real time by email
SC 13G/A 1 viractatherapeutics13ga.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

 

Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.)

(Name of Issuer)

 

 

Common Stock, par value $0.0001

(Title of Class of Securities)

 

 

92765F108

(CUSIP Number)

 

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[ ]       Rule 13d-1(b)

 

[X]       Rule 13d-1(c)

 

[ ]       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 1 
CUSIP No. 92765F108

 

1.Names of Reporting Persons.

Laurence W. Lytton

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization USA

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 255,876

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 255,876
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 255,876

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 0.7%

 

12.Type of Reporting Person (See Instructions) IN

 

 2 
CUSIP No. 92765F108

Item 1.

 

(a)Name of Issuer

Viracta Therapeutics, Inc. (f/k/a Sunesis Pharmaceuticals, Inc.)

 

(b)Address of Issuer's Principal Executive Offices

2533 S. Coast Hwy. 101, Suite 210, Cardiff, California 92007

 

Item 2.

 

(a)The names of the persons filing this statement are:

Laurence W. Lytton

(b)The principal business office of the Filers is located at:

467 Central Park West
New York, NY 10025

 

(c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

 

(d)This statement relates to shares of Common Stock, par value $0.0001 of the Issuer (the "Stock").

 

(e)The CUSIP number of the Issuer is: 92765F108
 3 
CUSIP No. 92765F108
Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

(e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

 

(f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

 

(g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

 

(h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

 

(k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

 

Item 4.Ownership.

 

See Items 5-9 and 11 of the cover page.

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 4 
CUSIP No. 92765F108

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2022

 

 

/s/ Laurence W. Lytton

Laurence W. Lytton

 

 

 

Get the next $VIRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VIRX

DatePrice TargetRatingAnalyst
8/16/2024$5.00 → $3.00Outperform → Market Perform
Leerink Partners
2/1/2022$10.00Outperform
RBC Capital Mkts
More analyst ratings

$VIRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Viracta Therapeutics Announces Wind Down of Operations

    SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

    SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety find

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

    - Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 - - Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors - SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VIRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VIRX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VIRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VIRX
SEC Filings

See more

$VIRX
Leadership Updates

Live Leadership Updates

See more
  • Viracta Therapeutics Announces Wind Down of Operations

    SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viracta Therapeutics Announces New Employment Inducement Grants

    SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each optio

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

    SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. "We are delighted to welcome Mike, an accomplished life sciences industry & Wall Street veteran, who we believe will be instrumental in supporting our next phase of development," said Mark Rothera, President and Chief E

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VIRX
Financials

Live finance-specific insights

See more
  • Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

    - New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8:

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

    – LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – LENZ Therapeutics, Inc. (NASDAQ:LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced th

    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VIRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more